During the first month of 2014 we have already witnessed multi-billion dollar M&A activity in the Biotechnology and Pharmaceutical industry and with almost $50 billion worth of revenue in pharmaceutical drugs going off-patent this year we are expecting an interesting 11 months to follow. In this Expert Guide we take a look at some of the Biggest Patent Expirations due to run its course whilst also exploring the latest developments in major jurisdictions such as Licensing Procedures & Classification in Italy, Life Sciences in North America and The Drive for Transparency in Australasia.

Click Here To View The Guide